# 主动脉内支架市场 > 主动脉内支架市场研究报告按产品类型（胸主动脉内支架、腹主动脉内支架、带孔主动脉内支架、分支主动脉内支架）、按终端用户（医院、门诊手术中心、专科诊所）、按手术类型（择期、急诊）、按材料（聚合物、金属、复合材料）以及按地区（北美、欧洲、南美、亚太、中东和非洲） - 预测至2035年 - **Forecast Period:** 2025 - 2035 - **CAGR:** 5.63% - **2024:** $ 3.75 Billion - **2025:** $ 3.96 Billion - **2035:** $ 6.85 Billion - **Key Players:** Medtronic (US), Gore Medical (US), Cook Medical (US), Boston Scientific (US), Terumo Corporation (JP), JOTEC GmbH (DE), Endologix (US), Cardinal Health (US), B. Braun Melsungen AG (DE) **Report ID:** MRFR/HC/34077-HCR · **Pages:** 128 · **Author:** Rahul Gotadki · **Last Updated:** August 24, 2026 **URL:** https://www.marketresearchfuture.com/reports/aortic-endograft-market-35974 --- ## Market Summary ## **Aortic Endograft Market Overview** As per MRFR analysis, the Aortic Endograft Market Size was estimated at 3.75 (USD Billion) in 2024. The Aortic Endograft Market Industry is expected to grow from 3.96 (USD Billion) in 2025 to 6.48 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 5.63% during the forecast period (2025 - 2034). ### **Key Aortic Endograft Market Trends Highlighted** The Global Aortic Endograft Market is currently shaped by several key drivers that foster its growth and development. Rising incidences of aortic aneurysms and vascular diseases fuel demand for minimally invasive surgical options. As healthcare providers seek effective ways to manage these conditions, advancements in technology and device efficacy create opportunities for better patient outcomes. Furthermore, an increased focus on improving patient recovery times drives the shift towards endovascular procedures, which are generally associated with lower complication rates. This trend indicates a strong move towards adopting innovative solutions that enhance the quality of care.The market also presents numerous opportunities for exploration and capture, particularly in emerging regions where healthcare infrastructure is expanding. Increased awareness and emphasis on preventive healthcare can create a demand for screening and early intervention. Collaborations and partnerships between device manufacturers and healthcare institutions can accelerate research and development, leading to the introduction of new and more effective endograft solutions. The rise of personalized medicine offers a path for creating tailored endograft therapies that accommodate individual patient needs, ultimately expanding market potential. Recent trends highlight a significant shift towards hybrid surgical techniques and the incorporation of advanced imaging technologies.Many healthcare providers are leveraging robotic-assisted surgeries to enhance precision in endograft placement. Additionally, the development of bioresorbable materials and designs that promote more natural healing processes reflects ongoing innovation in the market. Regulatory approvals for novel devices are also becoming more streamlined, facilitating quicker access to patients needing these critical interventions. The growing importance of patient-centered care continues to emphasize the need for effective, safe, and patient-friendly surgical options within the aortic endograft landscape. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **Aortic Endograft Market Drivers** ### **Increasing Incidence of Aortic Aneurysms** The Global Aortic Endograft Market Industry is primarily driven by the rising incidence of aortic aneurysms across the globe. Aortic aneurysms are abnormal bulges in the wall of the aorta, often leading to severe complications and health risks if not treated effectively. As populations age, the prevalence of cardiovascular diseases, including aortic conditions, is increasing. Advances in medical imaging and diagnostic techniques are enabling earlier detection of such conditions, leading to a growing pool of patients who can benefit from endovascular interventions.This growth is further fueled by lifestyle factors such as sedentary behavior, obesity, and smoking, which are contributing to higher rates of aortic diseases. As healthcare systems modernize and the demand for less invasive surgical procedures rises, the aortic endograft market is expected to expand significantly. Additionally, increasing awareness about the aortic disease and advancements in endograft technology, as improved materials and designs, are likely to enhance treatment options, ensuring better patient outcomes and driving the Global Aortic Endograft Market Industry forward. ### **Technological Advancements in Aortic Endografts** Technological innovation plays a critical role in shaping the Global Aortic Endograft Market Industry. The continuous development of advanced materials, designs, and technologies has improved the performance of endografts, making them more effective and safer for patients. Enhanced techniques for deployment and placement, combined with improved imaging technologies, facilitate more precise and successful interventions. Newer models of endografts offer better adaptability to various patient anatomies and conditions, thus widening the market scope.These technological advancements not only enhance the efficacy of treatments but also reduce recovery times and hospital stays for patients, increasing the attractiveness of aortic endografts as a treatment option. ### **Growing Demand for Minimally Invasive Procedures** With a shift in focus towards patient-centric care, there is a growing preference for minimally invasive procedures in the Global Aortic Endograft Market Industry. Patients and healthcare providers alike are recognizing the benefits of endovascular procedures over traditional open surgeries, such as shorter recovery times, reduced postoperative complications, and improved quality of life. This trend is prompting significant investment in research and development aimed at enhancing the safety and efficacy of endograft procedures.As awareness of the advantages of minimally invasive interventions continues to increase, the demand for aortic endografts is expected to rise, further propelling the market growth. ## **Aortic Endograft Market Segment Insights:** ### **Aortic Endograft Market Product Type Insights** The Global Aortic Endograft Market is experiencing steady growth driven by increasing awareness and the rising prevalence of aortic diseases. Within the broad Product Type segment, the market is categorized into Thoracic Aortic Endografts, Abdominal Aortic Endografts, Fenestrated Aortic Endografts, and Branched Aortic Endografts. In 2023, Thoracic Aortic Endografts were valued at 1.2 USD Billion, highlighting their significant role in treating thoracic aortic aneurysms. This segment shows strong growth potential, projected to reach 2.0 USD Billion in 2032. The importance of Thoracic Aortic Endografts is evident; they are crucial for emergency situations where immediate interventions are necessary. The Abdominal Aortic Endografts segment, with a valuation of 1.6 USD Billion in 2023, dominates this market due to the higher prevalence of abdominal aortic aneurysms globally.  This segment is expected to grow consistently, achieving a valuation of 2.6 USD Billion by 2032. The rising geriatric population and an increase in lifestyle-related diseases contribute significantly to the demand for this type of endograft treatment, illustrating its crucial importance in the Global Aortic Endograft Market. Fenestrated Aortic Endografts, valued at 0.8 USD Billion in 2023, offer a tailored solution to complex aortic anatomy, facilitating the treatment for patients with branched vessels. This segment is projected to witness growth, reaching an estimated 1.3 USD Billion by 2032. The unique design of fenestrated endografts makes them significant for specialized procedures, catering to a niche but vital area in aortic repair operations.  Branched Aortic Endografts, while valued lower at 0.32 USD Billion in 2023 and expected to rise to 0.61 USD Billion by 2032, play an essential role in aortic repair for patients with challenging anatomical configurations. The market growth for this segment indicates a growing recognition of the need for advanced surgical solutions. Overall, the continuing advancements in technology and increased preference for minimally invasive surgeries serve as growth drivers across all Product Types in the Global Aortic Endograft Market, while challenges such as high costs and a lack of trained professionals in this field provide hurdles to overcome as the industry evolves. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Aortic Endograft Market End User Insights** In 2023, the Global Aortic Endograft Market is expected to witness significant engagement from various End User categories, primarily encompassing hospitals, ambulatory surgical centers, and specialty clinics. Among these, hospitals hold a major share due to their comprehensive facilities and resources for handling complex procedures, making them a pivotal setting for aortic endograft deployments. Ambulatory surgical centers are on the rise as they offer a convenient and cost-effective alternative for less complicated surgeries, catering to a growing patient demand for outpatient procedures.Specialty clinics often focus on vascular health, thus playing a critical role in providing tailored care and advanced treatment options specifically for aortic conditions. The increase in cardiovascular diseases, coupled with the aging population, has paved the way for enhanced market growth. However, challenges such as high operational costs and regulatory constraints pose hurdles for these facilities. Nevertheless, the ongoing advancements in medical technologies and procedures present lucrative opportunities for innovation in the Global Aortic Endograft Market revenue generation and overall advancement in the industry.As the market data evolves, understanding these dynamics will be crucial for stakeholders. ### **Aortic Endograft Market Procedure Type Insights** The Global Aortic Endograft Market showcases distinct segmentation by Procedure Type, primarily categorized into Elective and Emergency procedures, reflecting the varied treatment requirements for aortic diseases. As of 2023, the overall market is valued at 3.36 billion USD, underscoring the increasing demand for innovative medical solutions in this field. Elective procedures are critical, often allowing for planned interventions that enhance patient outcomes and reduce surgical risks. They typically involve careful patient selection and timing, leading to smoother surgeries.Conversely, Emergency procedures address critical and urgent situations, often involving life-threatening conditions, making them highly significant in the aortic care spectrum. The importance of this segment is evident as it caters to unexpected medical crises, necessitating rapid interventions and highlights the urgency for effective endograft solutions. Overall, the Global Aortic Endograft Market revenue is expected to witness robust growth driven by advancements in technology and increasing awareness of aortic diseases, creating opportunities for improved treatment methodologies and patient care.Market growth is supported by the demand for effective management solutions that cater to both planned and unplanned medical scenarios within this essential healthcare domain. ### **Aortic Endograft Market Material Insights** The Global Aortic Endograft Market, valued at 3.36 billion USD in 2023, showcases a diverse segmentation in its Material component, which plays a vital role in the functionality and efficacy of aortic endografts. The demand for advanced materials, specifically Polymer, Metallic, and Composite, is rising as healthcare professionals seek improved solutions for aortic interventions. Polymers, known for their flexibility and biocompatibility, are increasingly preferred due to their adaptability in various medical settings. Metallic materials offer strength and durability, making them significant for high-pressure applications in aortic repairs.Composite materials combine the advantages of both polymers and metals, fostering innovative approaches that enhance the structural integrity of endografts. The trends within the Global Aortic Endograft Market indicate a shift towards materials that improve patient outcomes and longevity of devices. Factors such as an aging population, increasing prevalence of cardiovascular diseases, and advancements in material science are driving market growth. Challenges remain, including the need for long-term data on the performance of newer material technologies, yet the opportunities for market expansion remain robust, driven by healthcare innovations and rising demand for less invasive surgical options. ### **Aortic Endograft Market Regional Insights** The Global Aortic Endograft Market revenue showcases substantial growth across various regions. In 2023, North America dominates the market with a valuation of 1.56 USD Billion, and this segment is expected to grow to 2.51 USD Billion by 2032, reflecting its majority holding in the industry. Europe follows closely as the second-largest market, valued at 1.02 USD Billion in 2023, with an anticipated rise to 1.69 USD Billion in 2032, underscoring its significant role in this sector. The Asia-Pacific region holds a vital position, initially valued at 0.6 USD Billion in 2023, projecting growth to 1.0 USD Billion by 2032, reflecting an increasing demand for advanced healthcare solutions.South America and the Middle East Africa (MEA) contribute smaller shares, valued at 0.1 USD Billion and 0.08 USD Billion in 2023, respectively, with modest growth expected in the coming years, reaching 0.15 USD Billion by 2032. The growth in these regions is bolstered by the increasing prevalence of cardiovascular diseases and the rising adoption of minimally invasive surgeries, thus creating substantial opportunities for market expansion. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **Aortic Endograft Market Key Players and Competitive Insights:** The Global Aortic Endograft Market is witnessing significant growth driven by advancements in medical technology and an increasing prevalence of aortic aneurysms globally. As the market evolves, key players are focusing on innovation, product development, and strategic collaborations to enhance their competitive positioning. The landscape is characterized by a blend of established firms and emerging players, all vying for market share by offering various product lines tailored to meet the specific needs of healthcare providers and patients. The competitive environment is intensively shaped by regulatory challenges, reimbursement frameworks, and growing awareness of endovascular procedures, which are less invasive than traditional surgical interventions. In this dynamic market, differentiation through technology, effectiveness, and patient outcomes is increasingly pivotal for companies aiming to secure their foothold.JOTECH has carved out a notable presence in the Global Aortic Endograft Market through its commitment to quality and innovation.  The company focuses on developing advanced endovascular solutions that prioritize patient safety and optimal clinical outcomes. Its strengths lie in robust research capabilities and a strong pipeline of products designed to address varying anatomical challenges presented by aortic diseases. JOTECH's emphasis on quality control and testing ensure that its endografts not only meet but often exceed regulatory standards, enhancing its reputation among clinicians and hospitals alike. Furthermore, JOTECH fosters collaboration with healthcare professionals to gain insights that inform product development, ultimately translating into a competitive edge in the market.Terumo Corporation plays a significant role in the Global Aortic Endograft Market, bringing to the table a wealth of expertise in medical devices and a commitment to innovation.  The company's focus on research and development facilitates the creation of cutting-edge endograft solutions that align with current clinical needs and technological advancements. Terumo Corporation's global footprint and established distribution networks enable it to ensure the widespread availability of its products, fostering trust and reliance among healthcare providers. Its strength is accentuated by strategic partnerships that enhance its market reach, along with a strong emphasis on educational initiatives that empower clinicians with the knowledge needed to utilize its products effectively. The combination of these elements positions Terumo Corporation as a formidable competitor in the continuously evolving landscape of aortic endografts. ### **Key Companies in the Aortic Endograft Market Include:** ## Aortic Endograft Market Industry Developments - **Q2 2024: FDA Approves Medtronic's Valiant Navion Thoracic Stent Graft System for Expanded Indications** The FDA granted expanded approval for Medtronic's Valiant Navion Thoracic Stent Graft System, allowing its use in a broader range of thoracic aortic aneurysm and dissection cases. This regulatory milestone enables Medtronic to address more complex aortic pathologies with its endograft technology. - **Q2 2024: Terumo Receives CE Mark for RelayPro Thoracic Stent-Graft System** Terumo announced it has received CE Mark approval for its RelayPro Thoracic Stent-Graft System, enabling commercialization in the European Union. The device is designed for minimally invasive repair of thoracic aortic aneurysms. - **Q2 2024: Endologix Announces FDA Approval of ALTO Abdominal Stent Graft System** Endologix received FDA approval for its ALTO Abdominal Stent Graft System, a next-generation device for endovascular aneurysm repair (EVAR). The approval allows Endologix to market the device in the United States. - **Q3 2024: Boston Scientific Completes Acquisition of Veniti, Expanding Vascular Portfolio** Boston Scientific completed its acquisition of Veniti, a company specializing in venous stent technology, to strengthen its vascular intervention portfolio, including aortic endograft solutions. - **Q3 2024: Cook Medical Launches Zenith Fenestrated AAA Endovascular Graft in Japan** Cook Medical announced the commercial launch of its Zenith Fenestrated AAA Endovascular Graft in Japan following regulatory approval, expanding its global reach in the aortic endograft market. - **Q4 2024: Terumo Opens New Manufacturing Facility for Aortic Endografts in Ireland** Terumo inaugurated a new manufacturing facility in Ireland dedicated to the production of aortic endografts, aiming to meet growing global demand and enhance supply chain resilience. - **Q4 2024: Gore Receives FDA Approval for Conformable Excluder AAA Endoprosthesis** Gore announced FDA approval for its Conformable Excluder AAA Endoprosthesis, a device designed to treat abdominal aortic aneurysms with improved anatomical conformability. - **Q1 2025: Medtronic Launches Valiant Navion Thoracic Stent Graft System in China** Medtronic launched its Valiant Navion Thoracic Stent Graft System in China after receiving regulatory clearance, expanding its presence in the Asia-Pacific aortic endograft market. - **Q1 2025: Endologix Announces Strategic Partnership with Japanese Distributor for ALTO Device** Endologix entered a strategic partnership with a leading Japanese medical device distributor to commercialize its ALTO Abdominal Stent Graft System in Japan. - **Q2 2025: Boston Scientific Receives FDA Approval for New Aortic Stent Graft System** Boston Scientific received FDA approval for its latest aortic stent graft system, enabling the company to offer a new solution for endovascular aortic repair in the United States. - **Q2 2025: Gore Launches Next-Generation TAG Thoracic Endoprosthesis in Europe** Gore announced the European launch of its next-generation TAG Thoracic Endoprosthesis, designed for minimally invasive treatment of thoracic aortic aneurysms. - **Q2 2025: Terumo Announces Partnership with European Hospital Network for RelayPro Device** Terumo entered a partnership with a major European hospital network to provide its RelayPro Thoracic Stent-Graft System for clinical use in thoracic aortic aneurysm repair. ## **Aortic Endograft Market Segmentation Insights** ### **Aortic Endograft Market Product Type Outlook** ### **Aortic Endograft Market End User Outlook** ### **Aortic Endograft Market Procedure Type Outlook** ### **Aortic Endograft Market Material Outlook** ### **Aortic Endograft Market Regional Outlook** ## Market Drivers ### 医疗支出上升 主动脉内支架市场受到各地区医疗支出上升的积极影响。对医疗基础设施和服务的投资增加，促进了包括主动脉内支架在内的先进医疗技术的可用性。随着医疗系统将更多资源分配给创新治疗选择，血管内手术的可及性可能会改善。这一趋势在政府优先考虑医疗改革并扩大对微创手术的保险覆盖的地区尤为明显。因此，患者更有可能寻求主动脉疾病的治疗，从而导致对内支架的需求增加。此外，随着医疗支出的持续上升，制造商受到鼓励投资于研发，推出新的和改进的主动脉内支架产品。这一动态预计将进一步刺激主动脉内支架市场的增长。 ### 提高意识和教育 主动脉内支架市场正日益重视对主动脉疾病及其治疗选择的意识和教育。医疗专业人员和组织积极参与旨在教育临床医生和患者有关主动脉疾病相关风险的倡议。这种提高的意识至关重要，因为它鼓励早期诊断和及时干预，这对改善患者结果至关重要。此外，正在组织教育项目和研讨会，以告知医疗提供者有关血管内技术和技术的最新进展。因此，随着越来越多的临床医生意识到这些微创程序的好处，主动脉内支架的需求可能会增加。这一趋势也可能导致患者群体的知识水平提高，从而进一步推动主动脉内支架在临床实践中的采用。 ### 主动脉疾病发病率上升 主动脉内支架市场受到主动脉疾病（包括主动脉瘤和主动脉夹层）发病率上升的显著影响。流行病学研究表明，这些疾病的患病率正在上升，尤其是在老年人群中。随着全球人口老龄化，面临主动脉疾病风险的个体数量增加，从而推动了对有效治疗方案的需求。根据最新数据，主动脉瘤影响大约1-2%的65岁以上人群，突显了干预的迫切需求。这个不断增长的患者群体可能会推动主动脉内支架的采用，因为它们提供了传统外科手术方法的微创替代方案。因此，医疗服务提供者越来越多地转向血管内技术，这与更短的恢复时间和减少的住院时间相关，进一步促进了主动脉内支架市场的扩展。 ### 主动脉内支架市场的技术进步 主动脉内支架市场正在经历技术进步的激增，这些进步提高了血管内手术的有效性和安全性。下一代内支架的开发等创新，结合了先进的材料和设计特征，正变得越来越普遍。这些进展不仅改善了设备的耐用性和性能，还减少了手术期间和术后并发症的风险。例如，可定制内支架的引入允许针对个体患者解剖结构量身定制解决方案，从而优化治疗效果。此外，3D成像和实时监测等成像技术的整合正在彻底改变临床医生对主动脉干预的处理方式。因此，市场可能会见证强劲的增长轨迹，推动因素是对更安全和更有效治疗选择的需求。 ### 主动脉内支架市场的监管动态 主动脉内支架市场也受到持续的监管发展影响，这些发展旨在确保医疗设备的安全性和有效性。监管机构不断更新新型内支架技术的批准指南和标准，这可能会影响市场动态。例如，创新设备的快速审查流程的引入可能会促进新产品更快进入市场，从而增强竞争。此外，正在实施严格的市场后监督要求，以监测内支架的长期性能，确保其符合安全标准。这些监管变化不仅促进了创新，还增强了医疗服务提供者和患者对主动脉内支架可靠性的信心。因此，市场可能会受益于对研发的投资增加，从而推出满足不断变化的临床需求的先进产品。 ## Future Outlook 主动脉内支架市场预计将在2024年至2035年间以5.63%的年均增长率增长，推动因素包括技术进步、主动脉疾病的日益普遍以及医疗支出的增加。 **New opportunities:** - 为不同患者解剖结构开发可定制的内支架解决方案。 到2035年，主动脉内支架市场预计将实现显著增长和创新。 ## Segment Insights ### 按类型：腹主动脉内支架（最大）与胸主动脉内支架（增长最快） 在主动脉内支架市场中，细分市场的分布显示出腹主动脉内支架的显著领先，它们满足了更普遍和可接触的血管疾病的需求。紧随其后的是胸主动脉内支架，因为它们满足了治疗胸主动脉动脉瘤的关键需求，正在被越来越多地采用。尽管带孔和分支主动脉内支架在市场份额上较小，但在更复杂的解剖结构中发挥着重要作用，并且对有特定需求的患者至关重要。 主动脉内支架：腹部（主导）与胸部（新兴） 腹主动脉内支架在这一市场细分中占据主导地位，主要由于其在治疗常见主动脉疾病方面的有效性，导致更高的使用率和已建立的使用指南。这些内支架提供了如微创手术和患者恢复时间缩短等优势。相反，胸主动脉内支架正在快速增长，主要受到技术进步和对胸主动脉动脉瘤认识提高的推动。它们复杂的设计使得在具有挑战性的案例中能够有效治疗，从而捕获了专注于专业护理的市场中不断增长的细分。 ### 按最终用户：医院（最大）与门诊手术中心（增长最快） 在主动脉内支架市场中，医院目前占据最大的市场份额，主要是由于其全面的设施和熟练的外科团队，能够为主动脉疾病提供全方位的护理。他们配备了进行复杂手术所需的技术和专业知识，吸引了更多寻求先进治疗方案的患者，从而巩固了他们作为市场主导终端用户的地位。同时，门诊手术中心（ASC）也在快速增长，这得益于向门诊护理和微创手术的转变，使患者能够更快恢复并降低整体费用。 医院（主导）与门诊手术中心（新兴） 医院在主动脉内支架市场中仍然是主导者，因为它们能够提供全面的主动脉修复和管理解决方案。它们拥有先进的设施，包括成像技术和为复杂手术设计的手术室。患者通常更倾向于在医院进行重大手术，这也促成了它们更高的市场份额。另一方面，门诊手术中心正在成为市场中的一股重要力量，利用门诊手术的趋势。这些中心专注于效率和以患者为中心的护理，提供创伤更小、恢复时间更短的治疗选择。这一转变迎合了患者对方便、经济替代方案的偏好，同时减轻了医院资源的负担。 ### 按程序类型：择期（最大）与紧急（增长最快） 主动脉内支架市场按手术类型明显细分，其中选择性手术部分占据了重要份额。该部分吸引了能够计划治疗的患者，促进了其显著性。尽管紧急手术在整体市场分布中较小，但随着医疗系统增强处理紧急主动脉病症的能力，其相关性日益增加。这两个细分市场之间的差异反映了血管医学护理交付方式的不断演变。 手术类型：择期（主导）与紧急（新兴） 主动脉内支架市场中的选择性手术类型以其计划性为特征，这使得能够进行仔细的术前评估和患者准备。该细分市场通常涉及希望在方便的时间接受治疗的稳定主动脉动脉瘤患者，从而提高手术成功率和术后恢复。相反，急救细分市场已成为创新和资源分配的关键关注领域，旨在解决急性主动脉并发症患者的问题。该细分市场的快速增长受到微创技术和改进临床协议的推动，吸引了希望在危及生命的情况下改善患者结果的医疗服务提供者。 ### 按材料：聚合物（最大）与金属（增长最快） 在主动脉内支架市场中，材料细分为三种主要类型：聚合物、金属和复合材料。在这三者中，聚合物材料占据了最大的市场份额，主要得益于其优良的生物相容性和适应性。由于其轻便和易于制造，它们越来越受到青睐。同时，金属材料被认为是增长最快的细分市场，这得益于金属技术的进步，增强了其机械强度和耐用性，使其在复杂的主动脉修复中更具优势。 该细分市场的增长趋势与材料科学的创新以及对微创手术程序日益增长的需求密切相关。随着材料性能的改善，如灵活性和可扩展性，制造商正专注于开发结合聚合物和金属最佳特性的复合材料。这种融合预计将吸引更广泛的医疗保健客户群，表明材料细分市场整体将实现强劲增长。 材料：聚合物（主导）与复合材料（新兴） 在主动脉内支架市场中，聚合物材料因其在各种内支架设计中的多功能应用而脱颖而出。它们优越的柔韧性和与身体组织的兼容性促进了微创手术的实施，这在血管手术中越来越受到青睐。该细分市场受益于持续的研究与开发，旨在增强聚合物的性能。另一方面，复合材料虽然目前仍在崛起，但通过整合聚合物和金属的优点，正逐渐成为一个重要的替代品。它们提供了更好的强度与重量比和抗疲劳性，吸引了渴望创新解决方案的细分市场。随着制造商对这些复合材料选项的开发投入，预计它们的市场相关性将上升，从而在材料细分市场中带来更大的竞争。 ## Regional Market Share Analysis ### 北美：创新的市场领导者 北美是主动脉内支架的最大市场，约占全球市场份额的45%。该地区的增长受到先进医疗基础设施、主动脉疾病的日益普遍以及有利的报销政策的推动。FDA等机构的监管支持也催化了创新和产品批准，增强了市场动态。对微创手术的需求正在上升，进一步推动市场增长。美国是该地区的领先国家，拥有美敦力、戈尔医疗和库克医疗等主要企业。竞争格局以持续创新和关键参与者之间的战略合作为特征。加拿大在市场中也贡献显著，专注于改善医疗服务的可及性和患者的治疗效果。成熟公司的存在和持续的研究计划巩固了北美作为主动脉内支架技术中心的地位。 ### 欧洲：新兴的监管框架 欧洲是主动脉内支架的第二大市场，约占全球市场份额的30%。该地区的增长受到老龄化人口、对主动脉疾病的日益关注以及医疗技术的进步的推动。医疗器械法规（MDR）等监管框架正在提高产品的安全性和有效性，从而增强市场信心。德国和英国等国在采用创新解决方案方面处于领先地位，推动了整体市场的扩展。德国是欧洲主动脉内支架市场的关键参与者，JOTEC GmbH和B. Braun Melsungen AG等公司做出了重要贡献。竞争格局以成熟企业和新兴初创公司相结合，促进了创新。英国和法国也发挥着重要作用，正在进行临床试验和研究计划，旨在改善患者的治疗效果。强大的医疗系统和对研发的投资进一步增强了欧洲的市场地位。 ### 亚太地区：快速增长的市场潜力 亚太地区的主动脉内支架市场正在迅速增长，约占全球市场份额的20%。该地区的扩展受到医疗支出的增加、对心血管疾病的认识提高以及日益增长的老龄化人口的推动。日本和中国等国处于前沿，政府的支持性举措旨在改善医疗服务的可及性和质量。对先进医疗技术的需求也在上升，进一步推动市场增长。日本是该市场的领先国家，Terumo Corporation等公司做出了重要贡献。竞争格局正在演变，跨国公司和本地企业都在争夺市场份额。中国作为一个关键参与者正在崛起，受到快速城市化和医疗投资增加的推动。创新初创公司的存在和持续的研究计划预计将在未来几年增强市场格局，使亚太地区成为主动脉内支架技术的重要区域。 ### 中东和非洲：未开发的市场机会 中东和非洲地区在主动脉内支架市场中逐渐崭露头角，约占全球市场份额的5%。增长主要受到医疗投资增加、对心血管疾病的认识提高以及医疗基础设施改善的推动。南非和阿联酋等国专注于提升医疗设施和获取先进治疗的可及性，预计将在未来几年推动市场增长。南非是该地区的关键参与者，越来越多的医疗设施正在采用先进的医疗技术。竞争格局以本地和国际参与者的结合为特征，正在进行的合作旨在改善患者护理。阿联酋在医疗创新方面也取得了进展，政府举措支持先进医疗设备的采用。随着该地区的持续发展，主动脉内支架市场的增长潜力仍然显著。 ## Competitive Benchmarking 主动脉内支架市场的特点是动态的竞争格局，受到技术进步和主动脉疾病日益普遍的推动。主要参与者如美敦力（美国）、戈尔医疗（美国）和波士顿科学（美国）处于前沿，各自采取不同的策略以增强市场存在感。美敦力（美国）专注于通过开发下一代内支架进行创新，而戈尔医疗（美国）则强调与医疗服务提供者的合作，以改善患者结果。波士顿科学（美国）积极追求区域扩张，特别是在新兴市场，这共同塑造了一个既合作又竞争的环境。 在商业策略方面，公司越来越多地本地化制造，以降低成本并提高供应链效率。市场似乎适度分散，多个参与者争夺市场份额。然而，像Terumo Corporation（日本）和Cook Medical（美国）等主要公司的集体影响表明，行业正朝着整合的趋势发展，因为这些公司寻求利用其资源和能力以获得竞争优势。 在2025年8月，美敦力（美国）宣布推出其最新的主动脉内支架，该支架结合了先进的成像技术，以提高手术精确度。这一战略举措可能使美敦力在创新方面处于领先地位，可能吸引更广泛的客户群并改善患者结果。将尖端技术整合到其产品中也可能为行业设定新的标准，迫使竞争对手提升自身的技术能力。 在2025年9月，戈尔医疗（美国）与一家领先的远程医疗提供商达成战略合作，以促进患者术后远程监测。这一举措强调了戈尔致力于通过数字健康解决方案来提升患者护理的承诺，这不仅可能改善患者依从性，还可能降低医院再入院率。这一举措反映了将数字健康技术与传统医疗设备整合的趋势，从而增强整体价值主张。 在2025年10月，波士顿科学（美国）宣布收购一家专注于血管手术的人工智能驱动分析的小型公司。这一收购表明了将人工智能整合到医疗设备中的更广泛趋势，这可能显著提高手术结果和运营效率。通过整合人工智能能力，波士顿科学可能在竞争激烈的市场中脱颖而出，吸引寻求创新解决方案的医疗服务提供者。 截至2025年10月，主动脉内支架市场正在见证数字化、可持续性和人工智能整合等趋势。战略联盟越来越多地塑造竞争格局，因为公司认识到合作在推动创新中的价值。展望未来，竞争差异化预计将演变，从基于价格的竞争转向关注技术创新、改善患者结果和供应链可靠性。这一转变可能重新定义市场动态，迫使公司投资于研发和战略合作伙伴关系，以保持其竞争优势。 ## Recent News & Developments - **2024年第二季度：FDA批准美敦力的Valiant Navion胸主动脉支架系统扩展适应症** FDA授予美敦力的Valiant Navion胸主动脉支架系统扩展批准，允许其在更广泛的胸主动脉动脉瘤和夹层病例中使用。这个监管里程碑使美敦力能够利用其内支架技术处理更复杂的主动脉病理。 - **2024年第二季度：Terumo获得RelayPro胸主动脉支架系统CE标志** Terumo宣布已获得RelayPro胸主动脉支架系统的CE标志批准，使其能够在欧盟进行商业化。该设备旨在进行微创胸主动脉动脉瘤修复。 - **2024年第二季度：Endologix宣布ALTO腹主动脉支架系统获得FDA批准** Endologix获得FDA批准，其ALTO腹主动脉支架系统是一种用于血管内动脉瘤修复（EVAR）的下一代设备。该批准允许Endologix在美国市场销售该设备。 - **2024年第三季度：波士顿科学完成对Veniti的收购，扩展血管组合** 波士顿科学完成了对专注于静脉支架技术的Veniti公司的收购，以增强其血管介入组合，包括主动脉内支架解决方案。 - **2024年第三季度：Cook Medical在日本推出Zenith分支AAA血管内支架** Cook Medical宣布在获得监管批准后，在日本商业推出其Zenith分支AAA血管内支架，扩大其在主动脉内支架市场的全球影响力。 - **2024年第四季度：Terumo在爱尔兰开设新的主动脉内支架制造设施** Terumo在爱尔兰启用了一个新的制造设施，专门用于生产主动脉内支架，旨在满足日益增长的全球需求并增强供应链韧性。 - **2024年第四季度：Gore获得FDA批准用于可变形排除器AAA内支架** Gore宣布获得FDA批准，其可变形排除器AAA内支架是一种旨在治疗腹主动脉动脉瘤的设备，具有改善的解剖适应性。 - **2025年第一季度：美敦力在中国推出Valiant Navion胸主动脉支架系统** 美敦力在获得监管许可后，在中国推出其Valiant Navion胸主动脉支架系统，扩大其在亚太地区主动脉内支架市场的影响力。 - **2025年第一季度：Endologix宣布与日本分销商建立战略合作伙伴关系，推广ALTO设备** Endologix与一家领先的日本医疗设备分销商建立战略合作伙伴关系，以在日本推广其ALTO腹主动脉支架系统。 - **2025年第二季度：波士顿科学获得FDA批准的新型主动脉支架系统** 波士顿科学获得FDA批准其最新的主动脉支架系统，使公司能够在美国提供新的血管内主动脉修复解决方案。 - **2025年第二季度：Gore在欧洲推出下一代TAG胸内支架** Gore宣布在欧洲推出其下一代TAG胸内支架，旨在进行微创治疗胸主动脉动脉瘤。 - **2025年第二季度：Terumo宣布与欧洲医院网络建立合作关系，推广RelayPro设备** Terumo与一家主要的欧洲医院网络建立合作关系，为胸主动脉动脉瘤修复提供其RelayPro胸主动脉支架系统进行临床使用。 ## Report Scope | 2024年市场规模 | 3.748（十亿美元） | | --- | --- | | 2025年市场规模 | 3.959（十亿美元） | | 2035年市场规模 | 6.848（十亿美元） | | 复合年增长率（CAGR） | 5.63%（2024 - 2035） | | 报告覆盖范围 | 收入预测、竞争格局、增长因素和趋势 | | 基准年 | 2024 | | 市场预测期 | 2025 - 2035 | | 历史数据 | 2019 - 2024 | | 市场预测单位 | 十亿美元 | | 主要公司简介 | 市场分析进行中 | | 覆盖的细分市场 | 市场细分分析进行中 | | 主要市场机会 | 微创技术的进步增强了主动脉内支架市场的增长潜力。 | | 主要市场动态 | 技术进步和监管变化正在重塑主动脉内支架市场的竞争动态。 | | 覆盖的国家 | 北美、欧洲、亚太、南美、中东和非洲 | ## Frequently Asked Questions **Q: 到2035年，主动脉内支架市场的预计市场估值是多少？** A: 到2035年，主动脉内支架市场预计将达到68.48亿美元的估值。 **Q: 2024年主动脉内支架市场的市场估值是多少？** A: 2024年，主动脉内支架市场的价值为37.48亿美元。 **Q: 在2025年至2035年的预测期内，主动脉内支架市场的预期CAGR是多少？** A: 在2025年至2035年的预测期内，主动脉内支架市场的预期年复合增长率（CAGR）为5.63%。 **Q: 2024年，哪一段主动脉内支架的估值最高？** A: 在2024年，腹主动脉内支架细分市场的估值最高，达14.99亿美元。 **Q: 主动脉内支架市场的关键参与者有哪些？** A: 主动脉内支架市场的主要参与者包括美敦力、戈尔医疗、库克医疗和波士顿科学。 **Q: 到2035年，胸主动脉内支架的市场预计将增长多少？** A: 胸主动脉内支架细分市场预计将从2024年的11.24亿美元增长到2035年的20.48亿美元。 **Q: 到2035年，紧急程序类型细分市场的预计估值是多少？** A: 紧急程序类型细分预计到2035年将达到28亿美元的估值。 **Q: 到2035年，哪个最终用户细分市场预计将看到最大的增长？** A: 医院终端用户细分市场预计将从2024年的18.74亿美元增长到2035年的33.68亿美元。 **Q: 到2035年，复合材料部门的预计增长是多少？** A: 复合材料部门预计将从2024年的15亿美元增长到2035年的28.24亿美元。 **Q: 到2035年，窗孔主动脉内支架的市场与其他细分市场相比如何？** A: 窗孔主动脉内支架细分市场预计将从2024年的6.25亿美元增长到2035年的11.25亿美元，显示出稳定增长。 --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/aortic-endograft-market-35974*